Day: June 8, 2024

Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher than in the standard bimonthly aflibercept control group at all six timepoints through Week 24 Single intravitreal 3E10 vg/eye dose resulted in sustained reduction and stabilization of mean central subfield thickness (CST) compared to aflibercept at all timepointsIn the 3E10 vg/eye injection-free subgroup, the mean difference versus aflibercept in CST change from baseline for Weeks 20 and 24 was -31 microns in favor of 4D-150 Injection-free subgroup analyses reinforce previously reported positive 4D-150 Phase 2 PRISM topline results Interim 24-week landmark analysis from Phase 2 PRISM Population Extension cohort evaluating 4D-150 in broader...

Will send 10 Rogers customers, hockey fans and their guest to Game Four in Edmonton Will co-host game-day concerts with NHL for fans outside Rogers Place Will showcase real-time game updates on digital billboards throughout EdmontonTORONTO, June 08, 2024 (GLOBE NEWSWIRE) — Rogers today announced a national customer contest, Bring Stanley Home, to send Rogers customers and hockey fans from across Canada to the Stanley Cup Final in Edmonton. As the proud partner of the Edmonton Oilers and the NHL, the company will co-host free game-day concerts outside Rogers Place for games 3 and 4. “This is an exciting time for hockey fans across Canada, and we’re thrilled to celebrate Canada’s game with customer contests, concerts, and unique experiences for our customers and hockey fans,” said Terrie Tweddle, Chief Brand and Communications...

SOUTH SAN FRANCISCO, Calif., June 08, 2024 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with serious metabolic disorders marked by high unmet medical need, today announced two presentations featuring its lead product candidate efruxifermin (EFX) at the European Association for the Study of the Liver (EASL) Congress 2024, in Milan, Italy. The presentations will also be available on Akero’s website following the meeting. A late-breaking oral presentation will feature 96-week data from HARMONY, a Phase 2b study evaluating the efficacy and safety of EFX in patients with metabolic dysfunction-associated steatohepatitis (MASH), fibrosis stage 2 or 3 (F2–F3). The study met its primary endpoint of ≥1-stage improvement in fibrosis with...